Tyrosine Kinase Inhibitors: all 10,744 studies that test it

Page 107 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.

• Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical ProstatectomyTerminatedNCT00058266Phase 2
• Treatment With SU11248 in Patients With Neuroendocrine TumorsCompletedNCT00056693Phase 2
• Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.CompletedNCT00056459Phase 3
• Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal CancerCompletedNCT00056446Phase 3
• EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau SyndromeCompletedNCT00056199Phase 1
• CP-724,714 in Treating Patients With Metastatic Breast CancerCompletedNCT00055926Phase 1
• Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00055913Phase 1/2
• Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00055874Phase 3
• Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck CancerCompletedNCT00055770Phase 1/2
• Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma MultiformeStatus unknownNCT00054496Phase 2
• Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00054431Phase 2
• PTK787/ZK 222584 in Treating Patients With Unresectable Malignant MesotheliomaCompletedNCT00053885Phase 2
• Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00053248Phase 1/2
• Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung CancerCompletedNCT00052949Phase 2
• Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial SarcomaCompletedNCT00052754Phase 2
• Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal CancerTerminatedNCT00052585Phase 2
• Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT00052494Phase 1
• Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma MultiformeCompletedNCT00052208Phase 1/2
• Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584CompletedNCT00052013Phase 2
• A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast CancerCompletedNCT00051051Phase 2
• A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00050830Phase 2
• Gefitinib in Treating Patients With Cervical CancerCompletedNCT00049556Phase 2
• Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck CancerCompletedNCT00049283Phase 1
• Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00049192Phase 2
• Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal CancerCompletedNCT00049101Phase 1/2
• Therapy of Early Chronic Phase CML With GleevecCompletedNCT00048672Phase 2
• Iressa/Docetaxel in Non-Small-Cell Lung CancerWithdrawnNCT00048087Phase 2
• This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.CompletedNCT00047840Phase 2
• Efficacy Study of ZD6474 to Treat Multiple Myeloma CancerCompletedNCT00047788Phase 2
• A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung CancerCompletedNCT00047736Phase 3
• Study of Lonafarnib and Gleevec in Chronic Myelogenous LeukemiaCompletedNCT00047502Phase 1
• Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver DysfunctionCompletedNCT00047346Phase 1
• Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically RemovedTerminatedNCT00047333Phase 2
• Imatinib Mesylate in Treating Patients With Salivary Gland CancerCompletedNCT00045669Phase 2
• Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT00045604Phase 1
• Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach CancerCompletedNCT00045526Phase 2
• Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00045422Phase 2
• Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid TumorsActive, not recruitingNCT00045201Phase 1
• Imatinib Mesylate in Treating Patients With Metastatic Breast CancerCompletedNCT00045188Phase 2
• GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or OxaliplatinCompletedNCT00044343Phase 2
• Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic SyndromeActive, not recruitingNCT00044304Phase 2
• Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung CancerCompletedNCT00043823Phase 1/2
• Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian CancerTerminatedNCT00042952Phase 2
• Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT00042809Phase 1
• Imatinib Mesylate in Treating Patients With Stage IV Colorectal CancerCompletedNCT00041340Phase 2
• Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By SurgeryCompletedNCT00041197Phase 3
• Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder CancerCompletedNCT00041106Phase 2
• Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal CancerCompletedNCT00041041Phase 2
• Gefitinib in Treating Children With Refractory Solid TumorsCompletedNCT00040781Phase 1
• Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the MaculaCompletedNCT00040313Phase 2
• OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.CompletedNCT00040183Phase 3
• Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00040105Phase 1
• Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential TumorCompletedNCT00039585Phase 2
• Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain TumorsCompletedNCT00039494Phase 2
• Imatinib Mesylate in Treating Patients With MyelofibrosisCompletedNCT00039416Phase 2
• Gefitinib and Capecitabine in Treating Patients With Advanced Solid TumorsCompletedNCT00039390Phase 1
• Imatinib Mesylate in Treating Patients With GliomasCompletedNCT00039364Phase 2
• Erlotinib in Treating Patients With Malignant Mesothelioma of the LungCompletedNCT00039182Phase 2
• Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate CancerCompletedNCT00038194Phase 1
• Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal CancerCompletedNCT00036751Phase 2
• OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00036647Phase 3
• This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast CancerCompletedNCT00034918Phase 2
• Iressa Expanded Access Program (EAP)CompletedNCT00034879Phase 3
• Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2CompletedNCT00034281Phase 1
• Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder CancerCompletedNCT00033462Phase 2
• Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck CancerTerminatedNCT00033449Phase 1
• Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid TumorsCompletedNCT00033241Phase 1
• Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction CancerCompletedNCT00032123Phase 2
• Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal CancerCompletedNCT00032110Phase 2
• Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the CervixCompletedNCT00031993Phase 2
• Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone SarcomaCompletedNCT00031915Phase 2
• Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of ChildhoodCompletedNCT00030667Phase 2
• Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00030576Phase 1/2
• Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00030537Phase 2
• ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal CancerCompletedNCT00030524Phase 2
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial CancerCompletedNCT00030485Phase 2
• Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00030446Phase 2
• Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00030394Phase 2
• Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 MutationCompletedNCT00030186Phase 2
• Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00029003Phase 2
• Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid LeukemiaStatus unknownNCT00028847Phase 1/2
• Gefitinib in Treating Patients With Persistent or Recurrent Endometrial CancerCompletedNCT00027690Phase 2
• Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary GliomaCompletedNCT00027625Phase 1
• Imatinib Mesylate in Treating Patients With Metastatic MelanomaCompletedNCT00027586Phase 2
• Curcumin for the Prevention of Colon CancerCompletedNCT00027495Phase 1
• SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate CancerCompletedNCT00026377Phase 1
• Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic CancerCompletedNCT00026338Phase 3
• Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal CancerCompletedNCT00026299Phase 1/2
• SU5416 in Treating Patients With Persistent or Recurrent Cervical CancerCompletedNCT00026260Phase 2
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney FailureCompletedNCT00026169Phase 1
• Gefitinib in Treating Patients With Recurrent or Progressive CNS TumorsCompletedNCT00025675Phase 2
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
• Gefitinib in Treating Patients With Recurrent Metastatic Colorectal CancerCompletedNCT00025350Phase 2
• Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During SurgeryCompletedNCT00025246Phase 2
• Gefitinib in Treating Patients With Malignant MesotheliomaCompletedNCT00025207Phase 2
• Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal CancerCompletedNCT00025142Phase 2
• ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00025116Phase 2
• SU6668 in Treating Patients With Advanced Solid TumorsCompletedNCT00024206Phase 1
• Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast CancerCompletedNCT00024154Phase 2

← Tyrosine Kinase Inhibitors overview